Danielle Marie Brander

Journal Article Blood Adv · April 28, 2026 In the phase 3 randomized SEQUOIA study (NCT03336333), zanubrutinib (arm A) demonstrated superior progression-free survival (PFS) compared with bendamustine-rituximab (BR; arm B) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocyt ... Full text Link to item Cite

Retreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia.

Journal Article Hemasphere · December 2025 Full text Link to item Cite

View All Publications

Recent Grants

An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)

Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2019 - 2031

A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton?s Tyrosine Kinase Inhibitor (BTKi

Clinical TrialPrincipal Investigator · Awarded by Nurix Therapeutics, Inc. · 2026 - 2031

The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab

Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2025 - 2031

View All Grants

Education

Duke University, School of Medicine · 2007 M.D.